As mentioned earlier, DPP-4i are widely used antidiabetic agents primarily administered to T2D patients to prevent the degradation of incretins, such as GIP and GLP-1, by DPP-4 enzymes. This evidence concerns the gene GCG and type 2 diabetes mellitus.